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Background and Aims: Recent investigations have highlighted the value of
neuropsychological testing for the assessment and screening of Alcohol-Related Brain
Damage (ARBD). The aim of the present study was to evaluate the suitability of the
Addenbrooke’s Cognitive Examination (ACE-III) and the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS) for this purpose.
Methods: Comparing 28 participants with ARBD (11 with Korsakoff’s Syndrome
and 17 with the umbrella “ARBD” diagnosis) and 30 alcohol-dependent participants
without ARBD (ALs) we calculated Area Under the Curve (AUC) statistics,
sensitivity and specificity values, base-rate adjusted predictive values, and likelihood
ratios for both tests.
Results: High levels of screening accuracy were found for the total scores of both
the ACE-III (AUC = 0.823, 95% CIs [0.714, 0.932], SE = 0.056; optimal cut-off ≤86:
sensitivity = 82%, specificity = 73%) and RBANS (AUC = 0.846, 95% CIs [0.746,
0.947], SE = 0.052; optimal cut-off ≤83: sensitivity = 89%, specificity = 67%) at
multiple cut-off points. Removing participants with a history of polysubstance from
the samples (10 ALs and 1 ARBD) improved the diagnostic capabilities of the RBANS
substantially (AUC = 0.915, 95% CIs [0.831, 0.999], SE = 0.043; optimal cut-off ≤85:
sensitivity = 98%, specificity = 80%), while only minor improvements to the ACE-III’s
accuracy were observed (AUC = 0.854, 95% CIs [0.744, 0.963], SE = 0.056; optimal
cut-off ≤88: sensitivity = 85%, specificity = 75%).
Conclusion: Overall, both the ACE-III and RBANS are suitable tools for ARBD screening
within an alcohol-dependent population, though the RBANS is the superior of the
two. Clinicians using these tools for ARBD screening should be cautious of false-
positive outcomes and should therefore combine them with other assessment methods
(e.g., neuroimaging, clinical observations) and more detailed neuropsychological testing
before reaching diagnostic decisions.
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INTRODUCTION
It has been estimated that 50–80% of people who misuse alcohol
will experience some degree of cognitive impairment (Bernardin
et al., 2014). Deficits are primarily observed in memory, executive
abilities, visuospatial processing, speed of processing and, to a
lesser extent, attention and general intelligence (Stavro et al.,
2013). In chronic and severe cases of alcohol-dependence, the
neurocognitive impairment may progress to an extent where
more debilitating and permanent damage occurs. In such cases,
the person may receive a diagnosis of Alcohol-Related Brain
Damage (ARBD; Royal College of Psychiatrists, 2014), or one
of the more discretely defined diagnoses subsumed within this
larger conceptual category such as Korsakoff’s Syndrome (see
Heirene et al., 2018 for an overview of ARBD diagnoses).
Prompt recognition of ARBD is crucial to avoid further
deterioration and minimize the potentially deleterious effects
of cognitive dysfunction on treatment outcomes (Bates et al.,
2006). Recent investigations have found that neuropsychological
testing is highly effective at identifying individuals with ARBD
and distinguishing them from both healthy controls and alcohol-
dependent individuals with mild cognitive impairment (ALC).
For example, Wester et al. (2014) found that both the Rivermead
Behavioral Memory Test (RBMT; Wilson et al., 1989) and
California Verbal Learning Test (CVLT; Delis et al., 1987)
were useful in differentiating Korsakoff’s Syndrome (KS)—a
chronic form of ARBD characterized by severe episodic memory
deficits—from an ALC group, with statistically significant group
differences on every index of both tests. Wester et al. (2013a)
also found the updated RBMT-3 demonstrated high sensitivity
and specificity values when distinguishing between KS and ALC
groups, and between the latter group and healthy controls.
Brief cognitive screening tests have also proved useful for this
purpose. Wester et al. (2013b) found the Montreal Cognitive
Assessment (MoCA; Nasreddine et al., 2005) was able to
significantly differentiate between KS and ALC groups and
between KS and healthy controls, both with high sensitivity
and specificity values. What is more, when all of these
participants were ranked according to their RBMT-3 memory
score, the MoCA was also able to differentiate between those
classified as severely impaired and those deemed unimpaired,
between severely and mildly impaired groups, and between
mild and unimpaired groups all with good sensitivity and
specificity. Oudman et al. (2014) have also compared the ARBD
screening properties of the MoCA with the Mini-Mental Status
Examination (MMSE; Folstein et al., 1975). Comparing KS
and controls, both screening tests were able to significantly
differentiate between the groups with high sensitivity and
specificity, though the MoCA was the superior of the two.
Several other cognitive tests have been used to assess ARBD
but are yet to be specifically evaluated for this purpose.
In particular, the Addenbrooke’s Cognitive Examination-III
(ACE-III; Hsieh et al., 2013) and Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS) have been
used repeatedly to assess cognitive impairments in alcohol-
dependent individuals both with (e.g., Spiegel and Jim, 2011;
Wilson et al., 2012) and without (e.g., Green et al., 2010;
Rao, 2016) ARBD. Both the ACE-III and RBANS, whilst
comparatively short compared with batteries of global function
such as the Wechsler Adult Intelligence Scale, provide a more
extensive assessment of cognition than screening tests such as the
MMSE or MoCA. The combination of being relatively brief but
providing a more thorough assessment of cognitive function may
make these tools particularly suitable for use in alcohol treatment
services or hospital wards where time restrictions often apply, yet
a more detailed assessment is warranted than that provided by a
screening tool such as the MMSE or MoCA.
The ability of the previous version of the ACE-III, the
ACE-R, to identify cognitive impairments in alcohol-dependent
individuals without ARBD diagnoses was recently found to be
comparable to the MoCA and superior to the MMSE (Ridley
et al., 2017). The RBANS too, appears useful for identifying
alcohol-related cognitive impairments. Green et al. (2010) found
large effect sizes for comparisons between alcohol-dependent
individuals and controls on tests of immediate memory,
visuospatial abilities, and the overall test score. However, the
authors highlighted the RBANS’s inadequate assessment of
executive abilities as a limitation of the test. The same criticism
could also be said of the ACE-III, which assess only one
function classified under the rubric of executive function: verbal
fluency. This may restrict the use of both tests with this
population, as varying degrees of executive dysfunction have
become recognized as a central feature of ARBD (van Oort
and Kessels, 2009; Maharasingam et al., 2013). Nonetheless, the
accuracy of these tests for ARBD screening remains unknown.
Indeed, in a recent systematic review of studies evaluating the
value of multiple neuropsychological tests in the assessment
of alcohol-related cognitive impairment (Heirene et al., 2018),
the authors highlighted the ACE-III and RBANS as two tests
requiring further validation for ARBD assessment. Moreover, in
a recently completed prevalence study conducted by some of the
present authors (under review), the ACE-III and RBANS were the
most commonly used cognitive tests in the diagnosis of ARBD
in the United Kingdom. As a result, the aim of this study was
to evaluate the psychometric and diagnostic validity of the ACE-
III and RBANS for ARBD screening, and to compare the relative
value of the two tests for this purpose.
In the present study, a group of persons with ARBD diagnoses
was compared to alcohol-dependent individuals with no such
diagnosis (ALs). This comparison group was selected instead
of healthy controls as clinicians involved in the assessment of
cognition in alcohol-dependent individuals are likely to be more
focused on establishing whether the impairment is clinically
significant (i.e., likely to have a substantial impact on the person’s
ability to function on a day-to-day basis), as opposed to its
absence or presence. The ability to differentiate between these two
groups has important clinical implications as those with ARBD
may require the addition of cognitive rehabilitation strategies
to their treatment (Svanberg and Evans, 2013), as well as the
implementation of strategies to compensate for cognitive deficits
(Arts et al., 2017). Thus, if the two screening tests can differentiate
those with ARBD from those without, as has been found for other
commonly used screening measures (i.e., MoCA and MMSE),
then they can provide quick and relatively inexpensive methods
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of identifying those who may require more support than offered
by traditional treatments.
MATERIALS AND METHODS
Participants
A total of 60 persons agreed to participate in the study (AL:
n = 31, ARBD: n = 29). Prior to data collection, a power analysis
was performed using G∗Power (Faul et al., 2007) to determine
adequate sample size. Studies using the ACE-III and RBANS to
assess alcohol-related cognitive deficits are scant, though Green
et al. (2010) found large effect sizes (d = 1.08—1.17) on 3
of the RBANS’ scores between controls and moderate-heavy
alcohol consumers. Similarly, comparisons of the ACE-III total
score between cognitively impaired substance misusers (mostly
alcohol-related) and unimpaired controls in Ridley et al. (2017)
produced a very large effect size (d = 1.42; calculated by the
present authors based on descriptive statistics provided by Ridley
et al., 2017). Based on this demonstrated sensitivity to alcohol-
related cognitive deficits, a power calculation for a one-tailed
independent pairs t-test with an estimated medium-large effect
size (0.7; Cohen’s d), alpha at 0.5, and power at 0.8 estimated that
26 participants would be required in each group. A satisfactory
sample size was therefore achieved for both groups.
All ARBD participants were recruited through the Glasgow
specialist ARBD service. AL participants were recruited from
community rehabilitation services (i.e., non-profit addiction
support agencies; n = 20), hospital day-patient services (e.g.,
psychiatry, occupational therapy; n = 5), and secondary services
(e.g., community addictions services, psychology; n = 5). The
ARBD group comprised 11 persons with a diagnosis of KS and 18
with the umbrella diagnostic term “ARBD.” This latter diagnostic
conceptualization has been exposited by Wilson (2013) and
Wilson et al. (2011), who propound an inclusive and pragmatic
approach to the nosology of alcohol-related neurocognitive
decline which has now been adopted in United Kingdom
clinical practice. According to Wilson and colleagues, a person
with ARBD must meet two key criteria: [1] evidence of
cognitive impairment (as demonstrated by clinical examination
or cognitive testing) and [2] a significant history of alcohol misuse
(i.e., a minimum average of 35 standard drinks per week for men
and 28 for woman for a period of 5 years). The authors have
also proposed several other symptoms and behaviors that may
support the presence of ARBD (e.g., neuroimaging evidence of
cerebellar atrophy; frequent and/or delayed hospital admissions
attributable to their alcohol use or social and/or psychiatric
problems), as well as those that may indicate the presence of
complicating conditions (e.g., neuroimaging evidence of cortical
or subcortical infarction, subdural hematoma or other focal
brain pathology).
The origin of participants’ diagnoses varied and therefore
the exact procedures used to make diagnostic decisions was
unknown. However, in the Glasgow area, clinicians report
that ARBD diagnoses are—in line with Wilson and colleagues’
criteria (2011; 13)—typically made according to most or all
of the following criteria: [1] chronic and excessive alcohol
history, [2] evidence of cognitive deficits typically associated
with alcohol-dependence (e.g., impairments in episodic and
working memory, verbal fluency, and visuospatial processing),
[3] neuroimaging evidence of structural brain change, and [4]
psychosocial deterioration. KS diagnoses are typically made based
on the ICD-10 criteria for Alcohol-Related Amnesic Syndrome
(World Health Organisation, 1992), and also involves a
combination of assessing alcohol-use history, neuropsychological
testing, neuroimaging, and general clinical examination. All
AL participants met ICD-10 criteria for Dependence Syndrome
and had no evidence of ARBD. All diagnoses were made
independently of results from either the ACE-III or RBANS and
made by clinicians who were not part of the research team.
For inclusion in the study, participants were required to
be abstinent from alcohol and other substances (excluding
caffeine and nicotine) for a minimum of five-weeks at testing
and have no serious physical (e.g., severe hepatic disease) or
psychological (e.g., schizophrenia) complications. Less severe
psychological disorders (e.g., mild anxiety or depression) were
not criteria for exclusion. Due to the high incidence of head
injuries in this population it was considered unrealistic to exclude
individuals who had experienced any head injury. However,
evidence of severe brain injury (Glasgow Coma Scale: 3–8
(Teasdale and Jennett, 1974); Post-Traumatic Amnesia >7 days;
loss of consciousness: >24 h) or previous cranial surgery
were used as exclusion criteria. To meet the requirements of
testing, all participants were required to have use of their
dominant hand, adequate visual function, and not suffer from
receptive or expressive aphasia. Based on these criteria, one
AL participant was excluded for not meeting the minimum
abstinence requirement and one individual with an ARBD
diagnosis was excluded due to neuroimaging evidence of
intracranial hemorrhage within both frontal lobes resulting from
a traumatic brain injury.
The demographic and clinical characteristics of the final 58
participants are displayed in Table 1. Groups were approximately
matched for gender, medication use, and occupational status
distribution. The ARBD group were significantly older, had
a significantly longer duration of abstinence, were more
likely to have suffered from previous head injuries, and had
longer drinking histories on average; although these latter two
differences were not statistically significant. The AL group
contained significantly more individuals with a history of
polysubstance use (defined as using any illicit substance other
than cannabis [which was common among both groups] on
more than one occasion). Varying types and degrees of other-
substance use were reported by polysubstance users, including
the use of heroin, amphetamines, crack cocaine, cocaine, ecstasy,
and diazepam; still, alcohol was the primary substance used by all.
Measures
The ACE-III tests five cognitive domains: attention, memory,
verbal fluency, language, and visuospatial function. Individual
sub-test scores can be calculated as well as a total composite
score which has a maximum of 100. Two optimal cut-off points
for dementia have been identified that produce high levels of
sensitivity and specificity, 88 and 82, with the former resulting
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TABLE 1 | Characteristics of AL and ARBD participants.
Group Comparison
AL ARBD
n 30 28 (KS = 11;
ARBD = 17)
Gender:
male/female
19/11 18/10 χ2 = 0.057, p = 0.940
Age in years: M
(SD)
46.1 (8.9) 56.9 (7.2) t = 5.084, p < 0.001
Weeks of
abstinence: Mdn
(range)
19.5 (5–722) 70.5 (9–416) U = 207, p < 0.001
Drinking history
(years): Mdn (range)
16 (3–55) 20 (2–40) U = 354, p = 0.303
Poly-substance use
history: n (%)
10 (33.3) 1 (3.5) χ2 = 8.35, p = 0.004
Known previous
head injury: n (%)
1 (0.33) 6 (17.9) χ2 = 3.29, p = 0.070
Current medication use: n (%)
Antidepressants 17 (56.7) 15 (53.6) χ2 = 0.056, p = 0.813
Benzodiazepines 2 (6.7) 1 (3.6) χ2 = 0.283, p = 0.595
Antipsychotics 2 (6.7) 3 (10.7) χ2 = 0.301, p = 0.583
Disulfiram,
naltrexone,
acamprosate
6 (20.0) 2 (7.1%) χ2 = 2.01, p = 0.156
Occupational statusa: n (%)
Higher 4 (13.3) 4 (14.3) χ2 = 0.251, p = 0.882
Intermediate 6 (20.0) 7 (25.0)
Lower/unemployed 20 (66.7) 17 (60.7)
t = Welch’s t-test; U = Mann-Whitney U test (employed when data did not
meet parametric assumption of normal distribution); all t-tests and Man-Whitney
U tests were two-tailed; χ2 = Chi-square test (Fisher’s exact P value presented
where expected frequencies were < 5). aThe National Statistics Socio-Economic
Classification (Rose et al., 2005) was used to classify participants according to their
(previous or current) occupational status.
in superior sensitivity to specificity and the latter the obverse
(Hsieh et al., 2013; So et al., 2018). Administration and scoring
takes between 15 and 20 min and does not require specialist
training in psychometric testing; although introductory training
and familiarization with the test before use is recommended. The
test is currently available for free in 30 languages, in iPad and
mobile form, and in a miniature version. The Brain and Mind
Centre at the University of Sydney provide all versions of the test
for free, along with administration guidance1.
The RBANS contains 12 subtests which provide five
index scores: Immediate memory, Visuospatial/constructional,
Language, Attention, and Delayed memory. Combining these
index scores provides an overall performance score. All scores
are converted to age-adjusted norm scores which have a mean
of 100 and SD of 15. Normative data is available for participants
aged 12–89 years and four parallel versions of the test have been
developed for repeat testing, with forms A and B adapted to
United Kingdom use. Administration of the test typically takes
20–30 min. The test is available in over 20 languages and can
1https://sydney.edu.au/brain-mind/resources-for-clinicians/dementia-test.html
be purchased from Pearson Clinical Assessments. Pearson state
that the test can be used by allied health or special educational
professionals, as well as those with more formal training in
psychometric assessment.
Procedures
Potential participants were provided with written details of
the study by a professional contact (e.g., support worker, care
manager) and asked to arrange an appointment. All individuals
meeting inclusion criteria were fully informed of the study’s
procedures and provided written consent to participate and for
access to medical records to ensure there were no significant
complications which would preclude participation. Individuals
with ARBD were assessed within residential units, acute settings,
or within their own home. AL participants were all assessed in
day-patient settings (e.g., community addictions unit). The order
in which the two tests were presented was counterbalanced to
avoid order effects. Ethical approval was obtained from Greater
Glasgow and Clyde Health Board before commencing the study
(IRAS project ID: 155916).
Data Analysis
Analyses were conducted using jamovi (The jamovi project,
2019) and NCSS 2019. To enhance the reproducibility and
transparency of the analysis, the code used in jamovi to
analyze the data can be accessed via this project’s Open Science
Framework (OSF) page2 and in Supplementary Document 1.
This document also includes the full outcomes of all analyses,
including tests of statistical assumptions. Sensitivity and
specificity analyses were conducted using NCSS (2019) and the
associated AUC graphs were made using GraphPad (version 8),
therefore no code is available for these.
A combination of parametric and non-parametric tests
was used for between-group comparisons, the latter whenever
data were not normally distributed (Shapiro-Wilk’s test). For
comparisons using parametric tests, Welch’s t-test was used as
opposed to Student’s t as it is more robust to violations of
homogeneity of variance and more suitable when sample sizes
are uneven (see Delacre et al., 2017). As we made multiple
comparisons between the AL and ARBD groups on test scores,
we attempted to reduce the family-wise error rate by using a
Bonferroni correction. Dividing 0.05 by the number of score
comparisons (n = 12) resulted in an adjusted alpha of 0.0042 for
these comparisons.
Receiver Operator Characteristic (ROC) analyses were
conducted to determine the relative screening accuracy of the
ACE-III and RBANS. The ROC analysis provides sensitivity
(proportion of those with the disorder correctly identified
as impaired on the test) and specificity (proportion of those
without the disorder correctly identified as unimpaired on
the test) values, as well as an Area Under the Curve (AUC)
statistic. The AUC statistic varies between 0.5 and 1, with 1
representing perfect sensitivity and specificity. Positive and
Negative Predictive Values (PPV/NPV) were also calculated
to further evaluate the clinical utility of the tests. The PPV
2https://osf.io/m69nj/
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is the percentage of persons with a “positive” test score (i.e.,
within the impaired range) who actually have the disorder
(ARBD), and NPV is the percentage with a “negative” score
(i.e., within the normal range) who do not have the disorder.
Oudman et al. (2014) calculated the PPV and NPV for the
MMSE and MoCA, finding excellent predictive values for both
tools. However, their calculations did not reflect the base-
rate (prevalence) of ARBD in clinical settings, which directly
influences predictive values. In order to account for this, PPVs
and NPVs were calculated for the tests according to estimations
of ARBD prevalence (base-rate) within the alcohol-dependent
population. The proportion of alcohol-dependent individuals
believed to experience some form of major neurocognitive
disorder ranges from 12.5% (Zahr et al., 2011) up to 35% (Cook
et al., 1998). Accordingly, predictive values were calculated for
base-rates of 12.5% and 35% to reflect environments where
ARBD diagnoses are likely to be queried. Finally, positive
and negative likelihood ratios were calculated, which express
the probability of having the condition given a positive test
score and not having the condition given a negative test
score, respectively.
In accord with Simmons et al. (2012), we have reported
how we determined our sample size, all data exclusions, all
manipulations, and all measures used in the study.
RESULTS
Between-group comparisons for all test scores are presented in
Table 2, along with standardized (Cohen’s d, pooled SD used as
the standardizer) and unstandardized effect sizes to provide a
detailed understanding of findings (Lakens, 2013; Pek and Flora,
2018). The ARBD group scored significantly lower than ALs on
all test indices apart from the Attention and Visuospatial scores
of both tests; although, these differences (excluding that related
to the ACE-III visuospatial score) approached our adjusted
alpha level of 0.0042. According to Cohen’s (1992) classification
of effect sizes (i.e., small: d = 0.2, medium: d = 0.5, large:
d ≥ 0.8), large effects were observed on the ACE-III for the
Total score, Attention, Memory and Fluency, and small effects for
Language and Visuospatial scores. For the RBANS, large effects
were observed for Total score, Immediate Memory, and Delayed
Memory, while medium effects were found for Visuospatial,
Language and Attention.
As we identified multiple statistically significant differences
between the groups for the variables presented in Table 1, we
checked the robustness of the between-group differences on
each test score by running analyses of covariance (ANCOVAs)
for each comparison and including age, weeks of abstinence,
and polysubstance use history (coded as a categorical variables
with “yes” or “no” outcomes) as covariates in the models. All
statistically significant comparisons between groups at p < 0.004
reported in Table 2 remained significant at this adjusted
alpha level aside from the Fluency (p = 0.012) and Language
(p = 0.086) scores of the ACE-III. Thus, when accounting
for between-group differences in demographic and clinical
variables, it appears that discrepancies in memory scores most
differentiate the groups on both tests. The full outcomes for
all 12 ANCOVAs and the analysis code used to produce them
in jamovi are available on OSF (see text footnote 2) and in
Supplementary Document 1.
Several exploratory analyses were conducted on total test
scores to explore possible within-group differences. Alpha was set
at 0.05 to minimize the risk of false negative outcomes (i.e., Type-
II errors; see Hartgerink et al., 2017; Witt, 2019). The potential
adverse consequences associated with false-positive outcomes
(i.e., Type-I) in these exploratory analyses was deemed to be low
(Lakens et al., 2018). Nonetheless, the following outcomes should
be interpreted as reflecting exploratory, preliminary evaluations
of the data. First, due to the high number of ALs with a
history of polysubstance use, a within-group comparison between
those with a history of polysubstance use and those without
was undertaken. No significant difference was observed between
AL polysubstance users (n = 10, M = 85.5, SE = 3.5) and
ALs who only used alcohol (n = 20, M = 91.3, SE = 1.6) for
the ACE-III total score, t(12.9) = 1.52, p = 0.152, d = 0.68.
On the RBANS, however, a significant difference was found
between those with a polysubstance use history (M = 78.2,
SE = 4.1) and those without (M = 95.7, SE = 3.2) for the
total score, t(20.12) = 3.36, p = 0.003, d = 1.25. These poorer
scores could not be explained by differences in drinking history
duration (U = 83, p = 0.466) or length of abstinence (U = 75.5,
p = 0.289) between the two sub-groups. The ARBD group
was also dichotomized for further analysis into individuals
with a specific diagnosis of KS and those with the broad
“ARBD” diagnosis. No significant difference was found between
individuals with KS (n = 11; ACE-III: M = 77.1, SE = 3.5;
RBANS: M = 65.7, SE = 2.7) and those with ARBD (n = 17;
ACE-III: M = 79.5, SE = 2.3; RBANS: M = 71.5, SE = 3.1)
for ACE-III, t(18.4) = 0.568, p = 0.577, or RBANS scores,
t(25.9) = 1.4, p = 0.173.
ROC curves for the ACE-III and RBANS are displayed
in Figure 1. Table 3 displays test cut-off scores and their
corresponding diagnostic values, including the number of AL
and ARBD participants classed as impaired using this cut-
off, positive and negative predictive values, and positive and
negative likelihood ratios. Only cut-off scores that produced
optimal sensitivity (≥ 80%) and specificity (≥ 60%) levels
are presented, consistent with previous research in this area
(Oudman et al., 2014). The higher threshold for sensitivity over
specificity is consistent with the view that screening tests should
have high levels of sensitivity to maximize disease detection, while
subsequent assessments should have high levels of specificity
in order to ensure accurate diagnosis and avoid misdiagnosis
(McNamara and Martin, 2018).
The ACE-III total score was able to significantly differentiate
between the AL and ARBD participants (AUC = 0.823, 95% CIs
[0.714, 0.932], SE = 0.056, p < 0.001), with an optimal cut-off
score of ≤86 producing a sensitivity of 82% and specificity of
73%. Similarly, the RBANS total score significantly distinguished
between AL and ARBD participants (AUC = 8.46, 95% CIs
[0.746, 0.947], SE = 0.051, p < 0.001), with an optimal cut-
off score of ≤83 producing a sensitivity of 89% and specificity
of 67%. Although the AUC value was larger for the RBANS
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TABLE 2 | ACE-III and RBANS performance by alcohol-dependent individuals with and without ARBD.
Index (maximum score) M (SD), Mdn Comparison M diff [95% CIs]a Cohen’s d
AL ARBD
ACE-III Total score (100) 89.4 (8.90), 91.0 78.5 (10.3), 80.0 U = 149, p < 0.001 10.9 [5.80, 15.9] 1.14
Attention (18) 17.1 (1.17), 18.0 15.0 (2.97), 16.0 U = 225, p < 0.001 2.10 [0.88, 3.32] 0.94
Memory (26) 21.3 (3.98), 22.0 16.2 (4.57), 16.5 U = 156, p < 0.001 5.12 [2.86, 7.39] 1.20
Fluency (14) 12.0 (2.26), 13.0 9.79 (2.56), 10.0 U = 206, p < 0.001 2.21 [0.94, 3.49] 0.92
Language (26) 24.3 (2.85), 25.0 23.5 (1.60), 24.0 U = 239, p = 0.002 0.80 [−0.41, 2.01] 0.34
Visuospatial (16) 14.7 (1.29), 15.0 14.1 (1.84), 14.0 U = 341, p = 0.104 0.63 [−0.22, 1.48] 0.40
RBANS Total score 89.8 (16.1), 91.5 69.2 (11.6), 68.5 t = 5.62, p < 0.001 20.6 [13.3, 28.0] 1.46
Immediate memory 89.1 (18.7), 87.0 64.9 (13.7), 65.0 t = 5.65, p < 0.001 24.2 [15.6, 32.8] 1.47
Visuospatial 96.5 (20.8), 92.0 83.8 (17.8), 84.9 t = 2.52, p = 0.007 12.8 [2.62, 22.9] 0.66
Language 93.4 (11.5), 94.5 87.0 (7.10), 86.0 U = 229, p = 0.002 6.40 [1.41, 11.4] 0.67
Attention 91.0 (15.5), 89.5 80.4 (16.0), 82.0 t = 2.55, p = 0.007 10.5 [2.25, 18.8] 0.67
Delayed memory 91.8 (15.9), 94.0 62.8 (18.2), 58.0 t = 6.44, p < 0.001 29.0 [20.0, 38.0] 1.70
All tests one-tailed (ARBD < AL); Mean differences (M diff) and 95% CIs for Mann Whitney-U analyses are presented from Welch’s t outcomes for consistency with
parametric test outcomes. Means and medians (Mdn) are provided for consistency across outcomes and to present the most complete picture of findings. aTwo-tailed
confidence intervals presented to provide upper limits.
FIGURE 1 | ACE-III and RBANS ROC curves for differentiating between
alcohol-dependent individuals with and without ARBD.
than the ACE-III, the difference was not statistically significant
(discrepancy = 0.023, SE = 0.045, Z = 0.522, p = 0.602). As
AL participants with a history of polysubstance misuse scored
significantly lower than their alcohol-use-only counterparts on
the RBANS, two further exploratory ROC analyses were ran to see
how sensitivity and specificity values were affected by the removal
of all polysubstance users (see Figure 2 for ROC plot). This
removal resulted in minor improvements to diagnostic properties
of the ACE-III (AUC = 0.854, 95% CIs [0.744, 0.963], SE = 0.056,
p< 0.001; optimal cut-off =≤ 88: sensitivity = 85, specificity = 75)
and substantial improvements to the RBANS (AUC = 0.915, 95%
CIs [0.831, 0.999], SE = 0.043, p < 0.001; optimal cut-off: ≤85:
sensitivity = 96, specificity = 80). Again, the difference between
each test’s AUC value was not significant (discrepancy = 0.0611,
SE = 0.0511, Z = 1.196, p = 0.232).
Several exploratory correlational analyses were conducted to
investigate the relationships between participant characteristics
(i.e., duration of drinking history, duration of abstinence,
and age) and total test scores (alpha set at 0.05). None of
the correlations between the groups’ test scores and drinking
histories (rs range = −0.023 to −0.164, ps ≥ 0.388), age
(rs range = −0.003 to −0.173, ps ≥ 0.378), or length of
abstinence (rs range = −0.253 to 0.033, ps ≥ 0.194) were
significant [full outcomes reported on OSF (see text footnote 2)
and in Supplementary Document 1]. Both groups’ total ACE-
III and RBANS scores were significantly and strongly correlated
(AL: rs = 0.784, p< 0.001; ARBD rs = 0.700 p< 0.001), supporting
the convergent validity of the tests.
DISCUSSION
The present study aimed to evaluate the suitability of the
ACE-III and RBANS for ARBD assessment and their ability
to differentiate alcohol-dependent individuals with ARBD from
those without. Both measures produced significant between-
group differences on total scores and several sub- test scores,
although several significant effects for the ACE-III did not
remain when covariates were included in analysis models. Effect
sizes (d) were mostly in the medium-large range, indicating
a substantial discrepancy between the groups’ scores on both
tests. This was particularly the case for the subtests indexing
memory, which produced very large effects on both tests
(d ≥ 1.2) that were robust to the inclusion of covariables
in the models. Optimal sensitivity and specificity levels were
identified for the total scores of both tools at multiple
possible cut-off points. However, it should be noted that while
we selected our sensitivity and specificity thresholds of ≥80
and ≥60%, respectively, for consistency with similar studies
in this domain (Oudman et al., 2014), other authors have
recommended optimal thresholds of ≥80% should be used
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TABLE 3 | Diagnostic validity of the ACE-III and RBANS for differentiating between alcohol-dependent individuals with and without ARBD.
Comparison Cut-off Sensitivity/
specificity
No. ARBD/AL
classified as
impaired (%)
PPV (base-rate) NPV (base-rate) PLR NLR
(12.5%) (35%) (12.5%) (35%)
ACE-III ARBD vs. AL 86 82/73 23 (82)/8 (27) 30.1 62.4 96.6 88.4 3.08 0.24
87 82/70 23 (82)/9 (30) 28.1 59.6 96.5 87.9 2.80 0.26
88 86/67 24 (86)/10 (33) 26.9 58.1 97.0 89.7 2.60 0.21
90 86/63 24 (86)/11 (37) 25.0 55.7 96.9 89.2 2.32 0.23
Excluding polysubstance users:
ARBD (n = 27) vs. AL (n = 20)
86 81/75 22 (81)/5 (25) 31.8 63.7 96.6 88.3 3.26 0.25
88 85/75 23 (85)/5 (25) 32.7 64.7 97.3 90.4 3.41 0.20
RBANS ARBD vs. AL 81 82/70 23 (82)/9 (30) 28.1 59.6 96.4 87.9 2.74 0.26
82 86/67 24 (86)/10 (33) 26.9 58.1 97.0 89.7 2.60 0.21
83 89/67 25 (89)/10 (33) 27.7 59.1 97.8 92.0 2.70 0.16
84 89/63 25 (89)/11 (37) 25.8 56.7 97.6 91.7 2.44 0.17
85 96/63 27 (96)/11 (37 27.3 58.6 99.2 97.1 2.63 0.06
86 96/60 27 (96)/12 (40) 25.6 56.5 99.1 96.9 2.41 0.06
Excluding polysubstance users:
ARBD (n = 27) vs. AL (n = 20)
81 81/80 22 (81)/4 (20) 36.8 68.7 96.8 88.9 4.10 0.23
82 85/80 23 (85)/4 (20) 37.8 69.6 97.4 90.9 4.26 0.19
83 89/80 24 (89)/4 (20) 38.8 70.5 98.1 93.0 4.44 0.14
85 96/80 26 (96)/4 (20) 40.1 72.2 99.3 97.6 4.81 0.05
86 96/75 26 (96)/5 (25) 35.5 67.5 99.3 97.4 3.85 0.05
87 96/70 26 (96)/6 (30) 31.4 63.4 99.3 97.2 3.21 0.05
91 96/65 26 (96)/7 (35) 28.2 59.7 99.2 97.0 2.75 0.06
95 100/60 27 (100)/8 (40) 26.3 57.4 100 100 2.50 0.00
Emboldened cut-off scores produced the greatest sensitivity/specificity combination. Higher PPV and NPVs indicate better diagnostic accuracy (maximum = 1). Higher PLRs and lower NLRs indicate better diagnostic
accuracy. PPV and NPV, positive and negative predictive values; PLR and NLR, positive and negative likelihood ratios.
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FIGURE 2 | ACE-III and RBANS ROC curves for differentiating between
alcohol-dependent individuals with and without ARBD (excluding
polysubstance users).
for both values. Relatedly, although peak sensitivity values
were high for both the ACE-III (86%) and RBANS (96%),
specificity values peaked at 73% for the former and 70% for
the latter, highlighting a risk of false-positives when using such
cut-off scores.
Base-rate-adjusted positive and negative predictive values
were also calculated for both tests at ARBD prevalence rates
of 12.5 and 35%. At 12.5% prevalence, PPVs were low for
both the ACE-III (peak: 30.1%) and RBANS (peak: 28.1%),
further supporting a cautious interpretation of positive test
scores. As would be expected, these values increased considerably
when the prevalence rate was increased to 35% (ACE-III
peak: 62.4%; RBANS peak: 59.6%). NPVs were high for the
tests at 12.5% (ACE-III peak: 97%; RBANS peak: 99.2%) and
35% (ACE-III peak: 89.7%; RBANS peak: 97.1%) prevalence
rates, supporting confident interpretations of negative test
scores as true negatives. Overall, while predictive values were
better overall when using the increased base-rate of 35%, this
figure is predicated on the assumption that alcohol-related
cerebellar degeneration is part of the same disease process as
Wernicke-Korsakoff’s Syndrome (Cook et al., 1998) and may
therefore be an overestimation of ARBD prevalence in the
alcohol-dependent population.
Comparing the two tests, the diagnostic values produced
by the ACE-III appear largely commensurate with those of
the RBANS. However, some minor discrepancies between
the two are evident. First, while the conflated outcomes
of sensitivity and specificity values were approximately
equal between the two, the ACE-III produced a higher
level of specificity at its optimal cut-off (sensitivity = 82%,
specificity = 73%), while the RBANS had higher sensitivity
(sensitivity = 89%, specificity = 67%). This difference in
ability was reflected in greater PPVs and PLRs for the ACE-
III and greater NPVs and NLRs for the RBANS. Thus, the
ACE-III was more likely to correctly classify those without
the disorder as unimpaired than the RBANS, and the
RBANS was more likely to correctly classify those with the
disorder as impaired than the ACE-III. The availability of
parallel versions of the RBANS may contribute to its value
in assessing this population as repeat testing is required to
monitor any changes cognitive dysfunction over time and
in response to interventions (Royal College of Psychiatrists,
2014; Heirene et al., 2018). Thus, the RBANS can be used
for the monitoring of ARBD whilst circumventing the
issue of practice/learning effects associated with repeated
testing. Overall, if deciding between the two, the ACE-
III appears suitable when time restrictions are present,
though the more extensive RBANS should be considered
when time allows.
The diagnostic values of the ACE-III and RBANS found here,
while high, were lower than those for the MMSE and MoCA
observed by Oudman et al. (2014). However, the disparity is
likely because the authors compared those with ARBD (KS) to
healthy individuals – not ALs as was done here. Indeed, when
Wester et al. (2013b) compared KS participants with controls
the diagnostic values of the MoCA were superior to those
observed here, though when KS participants were compared
with an ALC group the sensitivity and specificity values did
not reach optimal levels (sensitivity = 73, specificity = 75). The
AL group in the present study demonstrated clear impairments
relative to norm scores on both measures, suggesting similarities
with the mildly impaired group studied by Wester et al.
(2013b). Thus, the screening capabilities of the ACE-III and
RBANS when comparing mildly versus severely impaired groups
may by superior to those of the MoCA; although a direct
systematic comparison would be required to confirm the
superior test(s).
This is the first study to directly evaluate the screening
capabilities of the ACE-III and RBANS for ARBD. Overall, the
findings support the use of both tests in clinical assessments
of alcohol-users; although caution should be taken to avoid
false-positive tests when using the cut-off points identified.
Our findings indicate that clinicians should observe individual
subtests scores as well as overall scores to best differentiate
those with ARBD from those without, with a particular
focus on memory scores. The present study also provides a
novel understanding of how using neuropsychological testing
in a screening capacity for ARBD is affected by a history
of polysubstance use. Findings from our exploratory analyses
indicated that those with a history of polysubstance use,
compared to those without such a history, will perform worse on
neuropsychological tests. The poor scores by AL polysubstance
users in the present study could not be explained by differences
in drinking history duration or length of abstinence, suggesting
it was the additional drug-use which compounded their alcohol-
related cognitive deterioration; however, we cannot be certain
of this from the data collected in this study. Bondi et al.
(1998) reported a similar significant decrease in performance
on selective tasks by ALs with concurrent polysubstance use
compared to those who only used alcohol; still, causation
cannot be inferred from these findings. Overall, our findings
suggest a consideration of previous drug use should be
made when cognitively assessing alcohol users as this may
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also contribute to impairment. Nonetheless, it is likely the
degree of impairment, as opposed to its etiology, that is of
interest to clinicians.
This is also one of the first studies to investigate the value
of neuropsychological testing in the detection of ARBD, as
opposed to more discretely defined diagnoses such as KS.
The recent impetus for using ARBD as a broad conceptual
diagnostic term has been motivated by heterogeneity within those
diagnosed with KS, including varying numbers of individuals
with executive (van Oort and Kessels, 2009) and/or intellectual
(Jacobson and Lishman, 1987) deficits, as well as a high
prevalence of head injuries, liver disease and other factors
which can confound neurocognitive impairment and create
further inter-person variability. Indeed, Bowden (1990) has
argued that the rigid selection criteria implemented by KS
researchers may render their samples artifacts of this process
which are, as a result, unrepresentative of the heterogeneous
presentation more typical of this population. Comparing the
two diagnostic sub-divisions of the ARBD group, no statistically
meaningful difference was identified between those with KS
and those with ARBD on the total scores of the ACE-III
or RBANS; although the sample sizes were small, potentially
limiting the ability to detect any subtle differences. Due to small
sample sizes, no further differences between the sub-groups’
scores were explored. Future research should compare larger
samples of persons with KS and ARBD to explore whether
differences in cognitive profiles underpin the choice of diagnostic
nomenclature in modern clinical settings, thereby evaluating the
merit of the distinction.
The primary limitation of this study was the absence
of a reference standard assessment to confirm the existing
diagnosis in the ARBD population. However, as previously
stated, ARBD diagnoses in the study area are made against
rigorous criteria by the Glasgow ARBD service which specializes
in the diagnosis and treatment of those with the condition.
Additionally, the ARBD group had significantly longer drinking
histories and consistently poorer scores on both the ACE-III and
RBANS, supporting the diagnostic distinction between groups.
A second limitation was the significant difference between
groups in regards to age, polysubstance use history, and weeks
of abstinence. Although, to account for these differences, we
ran ANCOVAs for all group comparisons and included these
variables as covariates and have transparently reported all
outcomes from these in addition to t-test and Mann-Whitney-U
outcomes (Supplementary Document 1).
While the ACE-III and RBANS can be used to screen
several different neurocognitive disorders (including mild
cognitive impairment and various dementias; Karantzoulis
et al., 2013; Bruno and Schurmann Vignaga, 2019), two
screening tests have been developed recently specifically
for assessing alcohol-related cognitive impairments. The
first of these, the BEARNI (Brief Examination of Alcohol-
related Neuropsychological Impairments; Ritz et al., 2015),
was designed to be easily administered by non-specialists
and assesses working and episodic memory, visuospatial
skills, executive function, and ataxia. The second test, the
TEDCA (Test of Detection of Cognitive Impairment in
Alcoholism; Jurado-Barba et al., 2017), assesses working
and episodic memory and visuospatial skills. Both tests
may provide equally, if not superior, screening capabilities
to the ACE-III and RBANS for ARBD detection, though
neither test has been specifically validated for the screening of
clinically diagnosed alcohol-related neurocognitive disorders
(e.g., KS, ARBD). The BEARNI was found to have very high
sensitivity (100%) for detecting individuals with cognitive
impairment (as determine by detailed neuropsychological
assessment) within a sample of ALs, although the specificity
of the test was very poor (4%; Pelletier et al., 2018). In the
same sample, the MoCA demonstrated 79% sensitivity and
65% specificity. Future research in this domain should focus
on evaluating the screening capabilities of both tests for the
populations studied here to determine whether they may better
replace more generalized tests used in clinical practice (e.g.,
ACE-III, MoCa etc.).
In sum, the present findings add to a recent body of
evidence suggesting that neuropsychological tests can be used
effectively to inform the ARBD diagnostic process. The two
tests studied here are more extensive in their assessment
of cognition than the cognitive screening tests previously
investigated for this purpose (i.e., MoCA and MMSE) and can
therefore provide a more comprehensive overview of impaired
and preserved cognitive abilities, whilst still remaining relatively
quick to administer. Nonetheless, screening tests alone should
not be used to confirm ARBD diagnoses (Heirene et al.,
2018). Informed diagnostic decision making and treatment
planning require more thorough assessments of cognition
to detail the severity of impairment and the specific skills
affected. In particular, further assessment of executive function
(e.g., Behavioral Assessment of the Dysexecutive Syndrome)
is warranted as both the ACE-III and RBANS lack sufficient
testing of this domain. Finally, it is important to note
that while neuropsychological testing is an important and
informative feature of ARBD assessment, so too are clinical
observations, assessments of activities of daily living, nutritional
status investigations, and neuroimaging procedures (Horton
et al., 2015), and thus each should be used in conjunction
whenever possible.
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